What is the share price of Parmax Pharma Ltd (PARMAX) today?
The share price of PARMAX as on 11th July 2025 is ₹42. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Parmax Pharma Ltd (PARMAX) share?
The past returns of Parmax Pharma Ltd (PARMAX) share are- Past 1 week: -3.23%
- Past 1 month: 3.77%
- Past 3 months: -14.18%
- Past 6 months: 2.46%
- Past 1 year: 22.20%
- Past 3 years: 23.53%
- Past 5 years: 41.89%
What are the peers or stocks similar to Parmax Pharma Ltd (PARMAX)?
The peers or stocks similar to Parmax Pharma Ltd (PARMAX) include:What is the market cap of Parmax Pharma Ltd (PARMAX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parmax Pharma Ltd (PARMAX) is ₹157.13 Cr as of 11th July 2025.What is the 52 week high and low of Parmax Pharma Ltd (PARMAX) share?
The 52-week high of Parmax Pharma Ltd (PARMAX) is ₹55.02 and the 52-week low is ₹31.50.What is the PE and PB ratio of Parmax Pharma Ltd (PARMAX) stock?
The P/E (price-to-earnings) ratio of Parmax Pharma Ltd (PARMAX) is -74.83. The P/B (price-to-book) ratio is 2244.78.Which sector does Parmax Pharma Ltd (PARMAX) belong to?
Parmax Pharma Ltd (PARMAX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Parmax Pharma Ltd (PARMAX) shares?
You can directly buy Parmax Pharma Ltd (PARMAX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Parmax Pharma Ltd
PARMAX Share Price
42.003.78% (+1.53)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PARMAX Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
PARMAX Performance & Key Metrics
PARMAX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -74.83 | 2,244.78 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.68 | 6.41 | 0.79% |
PARMAX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PARMAX Company Profile
Parmax Pharma Ltd engages in the production of active pharmaceutical ingredients (APIs) and contract manufacturing, adhering to cGMP standards for complex molecules.
SUNPHARMA
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
PARMAX Forecast
PARMAX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARMAX
PARMAX
Income
Balance Sheet
Cash Flow
Annual Normal View
PARMAX Income Statement
PARMAX Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.06 | 11.94 | 12.04 | 21.02 | 26.29 | 18.31 | 15.46 | 11.10 | 28.24 | 28.24 | ||||||||||
Raw Materials | 0.00 | 7.06 | 5.74 | 9.79 | 13.96 | 6.29 | 5.51 | 7.03 | 29.02 | 29.02 | ||||||||||
| Power & Fuel Cost | 0.00 | 1.48 | 1.77 | 2.26 | 2.09 | 2.31 | 1.98 | 2.23 | ||||||||||||
| Employee Cost | 0.02 | 2.13 | 2.08 | 2.91 | 3.54 | 3.46 | 2.80 | 2.91 | ||||||||||||
| Selling & Administrative Expenses | 0.04 | 0.43 | 0.71 | 0.70 | 0.95 | 1.03 | 0.87 | 0.73 | ||||||||||||
| Operating & Other expenses | -0.01 | -0.30 | 0.58 | 3.48 | 2.24 | 2.61 | 2.01 | 1.52 | ||||||||||||
EBITDA | 0.01 | 1.14 | 1.16 | 1.88 | 3.51 | 2.61 | 2.29 | -3.32 | -0.78 | -0.78 | ||||||||||
| Depreciation/Amortization | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 1.03 | ||||||||||
| PBIT | 0.01 | 0.05 | 0.13 | 0.87 | 1.57 | 0.68 | 0.41 | -5.03 | -1.81 | -1.81 | ||||||||||
| Interest & Other Items | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 0.59 | ||||||||||
| PBT | 0.01 | 0.01 | 0.10 | 0.74 | 1.20 | 0.29 | 0.04 | -5.65 | -2.40 | -2.40 | ||||||||||
| Taxes & Other Items | 0.01 | 0.01 | 0.02 | 0.30 | 0.46 | 0.17 | 0.15 | 0.12 | -0.30 | -0.30 | ||||||||||
| Net Income | -0.00 | 0.00 | 0.08 | 0.44 | 0.74 | 0.12 | -0.11 | -5.77 | -2.10 | -2.10 | ||||||||||
| EPS | -0.00 | 0.00 | 0.12 | 0.76 | 1.36 | 0.21 | -0.30 | -14.67 | -5.60 | -3.25 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PARMAX Company Updates
PARMAX Stock Peers
PARMAX Past Performance & Peer Comparison
PARMAX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parmax Pharma Ltd | -74.83 | 2,244.78 | — |
| Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
| Cipla Ltd | 22.75 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
PARMAX Stock Price Comparison
Compare PARMAX with any stock or ETFCompare PARMAX with any stock or ETF
PARMAX
PARMAX Holdings
PARMAX Shareholdings
PARMAX Promoter Holdings Trend
PARMAX Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PARMAX Institutional Holdings Trend
PARMAX Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARMAX Shareholding Pattern
PARMAX Shareholding Pattern
PARMAX Shareholding History
PARMAX Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PARMAX stock
smallcases containing PARMAX stock
Looks like this stock is not in any smallcase yet.
PARMAX Events
PARMAX Events
PARMAX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARMAX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PARMAX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARMAX has not given any dividends in last 5 years
PARMAX Dividends
PARMAX Dividends
Hmm, looks like data is unavailable here. Please come back after some timePARMAX Stock News & Opinions
PARMAX Stock News & Opinions
Articles & Videos
Earnings
Parmax Pharma reports standalone net loss of Rs 1.49 crore in the March 2025 quarter
Net Loss of Parmax Pharma reported to Rs 1.49 crore in the quarter ended March 2025 as against net loss of Rs 1.45 crore during the previous quarter ended March 2024. Sales rose 13.38% to Rs 4.83 crore in the quarter ended March 2025 as against Rs 4.26 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 2.09 crore in the year ended March 2025 as against net loss of Rs 5.75 crore during the previous year ended March 2024. Sales rose 155.20% to Rs 28.20 crore in the year ended March 2025 as against Rs 11.05 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales4.834.26 13 28.2011.05 155 OPM %-11.59-18.78 -0.92-30.59 - PBDT-0.90-0.95 5 -0.29-3.95 93 PBT-0.72-1.36 47 -1.32-5.66 77 NP-1.49-1.45 -3 -2.09-5.75 64 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Parmax Pharma schedules board meeting
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Parmax Pharma reports standalone net loss of Rs 0.39 crore in the December 2024 quarter
Net Loss of Parmax Pharma reported to Rs 0.39 crore in the quarter ended December 2024 as against net loss of Rs 1.75 crore during the previous quarter ended December 2023. Sales rose 372.18% to Rs 6.28 crore in the quarter ended December 2024 as against Rs 1.33 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales6.281.33 372 OPM %1.91-86.47 - PBDT0.02-1.30 LP PBT-0.39-1.75 78 NP-0.39-1.75 78 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Parmax Pharma to conduct board meeting
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Parmax Pharma reports standalone net loss of Rs 0.22 crore in the September 2024 quarter
Net Loss of Parmax Pharma reported to Rs 0.22 crore in the quarter ended September 2024 as against net loss of Rs 1.37 crore during the previous quarter ended September 2023. Sales rose 128.01% to Rs 9.28 crore in the quarter ended September 2024 as against Rs 4.07 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales9.284.07 128 OPM %2.05-18.92 - PBDT0.18-0.94 LP PBT-0.22-1.37 84 NP-0.22-1.37 84 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Parmax Pharma to discuss results
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Parmax Pharma to conduct AGM
Parmax Pharma announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Parmax Pharma reports standalone net profit of Rs 0.01 crore in the June 2024 quarter
Net profit of Parmax Pharma reported to Rs 0.01 crore in the quarter ended June 2024 as against net loss of Rs 1.18 crore during the previous quarter ended June 2023. Sales rose 458.57% to Rs 7.82 crore in the quarter ended June 2024 as against Rs 1.40 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales7.821.40 459 OPM %6.52-46.43 - PBDT0.41-0.76 LP PBT0.01-1.18 LP NP0.01-1.18 LP Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Parmax Pharma to declare Quarterly Result
Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.08%, vs industry avg of 10.1%
Over the last 5 years, market share stayed at 0.01%